News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
The companies plan to use machine learning and simulation to study disease drivers and identify existing and new therapies, focusing first on cardiovascular disease.
At the WIN Symposium, a Merck executive detailed how data from a basket study led to the first pan-cancer, biomarker-informed cancer drug.
The consortium conducts basic science on the structures of human proteins and releases the research to the public.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.